Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BTAI NASDAQ:BYND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.00-4.8%$2.07$0.98▼$4.46$690.31M0.4610.19 million shs7.76 million shsBTAIBioXcel Therapeutics$0.82-2.4%$1.18$0.74▼$8.08$25.24M0.271.20 million shs711,203 shsBYNDBeyond Meat$0.66-2.8%$0.75$0.50▼$7.69$338.07M2.7528.72 million shs36.34 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-3.85%+6.38%-26.47%+65.29%BTAIBioXcel Therapeutics0.00%-40.76%-26.35%-22.88%-59.13%BYNDBeyond Meat0.00%-7.64%-6.79%+9.96%-81.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.00-4.8%$2.07$0.98▼$4.46$690.31M0.4610.19 million shs7.76 million shsBTAIBioXcel Therapeutics$0.82-2.4%$1.18$0.74▼$8.08$25.24M0.271.20 million shs711,203 shsBYNDBeyond Meat$0.66-2.8%$0.75$0.50▼$7.69$338.07M2.7528.72 million shs36.34 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-3.85%+6.38%-26.47%+65.29%BTAIBioXcel Therapeutics0.00%-40.76%-26.35%-22.88%-59.13%BYNDBeyond Meat0.00%-7.64%-6.79%+9.96%-81.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52326.11% UpsideBTAIBioXcel Therapeutics 2.25Hold$11.001,245.57% UpsideBYNDBeyond Meat 1.33Strong Sell$0.8325.76% UpsideCurrent Analyst Ratings BreakdownLatest BYND, ALLO, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026BYNDBeyond Meat Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/1/2026BYNDBeyond Meat Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral4/14/2026ALLOAllogene Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.004/14/2026ALLOAllogene Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/14/2026ALLOAllogene Therapeutics ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$5.00 ➝ $8.004/14/2026ALLOAllogene Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.00(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ABTAIBioXcel Therapeutics$640K39.44N/AN/A($4.37) per share-0.19BYNDBeyond Meat$275.50M1.23N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)BTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)BYNDBeyond Meat$219.02M-$2.22N/AN/AN/A54.95%-54.39%32.46%8/5/2026 (Estimated)Latest BYND, ALLO, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026BYNDBeyond Meat-$0.08N/AN/AN/A$62.43 millionN/A5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/6/2026Q1 2026BYNDBeyond Meat-$0.12-$0.10+$0.02-$0.06$58.02 million$58.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ABYNDBeyond MeatN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65BTAIBioXcel TherapeuticsN/A0.620.61BYNDBeyond MeatN/A2.852.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BTAIBioXcel Therapeutics30.68%BYNDBeyond Meat52.48%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BTAIBioXcel Therapeutics3.70%BYNDBeyond Meat1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.16 million299.60 millionOptionableBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataBYNDBeyond Meat880515.34 million505.55 millionOptionableBYND, ALLO, and BTAI HeadlinesRecent News About These CompaniesBeyond Meat (NASDAQ:BYND) Upgraded at Wall Street ZenJuly 12 at 1:17 PM | marketbeat.comBeyond Meat, Inc. (NASDAQ:BYND) Receives $0.82 Average PT from BrokeragesJuly 10 at 3:45 AM | americanbankingnews.comWhat Prediction Markets Say About 3 of America’s Most At-Risk BrandsJuly 9 at 12:42 PM | 247wallst.com3 Reasons BYND is Risky and 1 Stock to Buy InsteadJuly 9 at 12:42 PM | finance.yahoo.comWhat Prediction Markets Say About 3 of America's Most At-Risk BrandsJuly 9 at 8:15 AM | 247wallst.com3 reasons BYND is risky and 1 stock to buy insteadJuly 9 at 7:41 AM | msn.comBeyond Meat, International Flavors & Fragrances, and Vital Farms Shares Plummet, What You Need To KnowJuly 8, 2026 | finance.yahoo.comBeyond Meat Expands Steak Filet Reach as Turnaround Efforts ContinueJuly 8, 2026 | finance.yahoo.comBeyond Meat Expands Steak Filet Reach as Turnaround Efforts ContinueJuly 8, 2026 | zacks.comWhat Does Beyond Meat (NASDAQ:BYND) Meijer Rollout Mean for Nasdaq Composite?July 8, 2026 | kalkinemedia.comKBeyond Meat® to Introduce Beyond Steak® Filet at Meijer This MonthJuly 7, 2026 | finance.yahoo.comBeyond Meat® to Introduce Beyond Steak® Filet at Meijer This MonthJuly 7, 2026 | globenewswire.comPerishable Food Stocks Q1 Highlights: Beyond Meat (NASDAQ:BYND)July 6, 2026 | finance.yahoo.comBeyond Meat Inc. stock falls Thursday, underperforms marketJuly 3, 2026 | marketwatch.comWhy Beyond Meat Stock Is Up TodayJune 30, 2026 | fool.comHow Is Beyond Meat Expanding Its Retail Distribution Strategy?June 30, 2026 | finance.yahoo.comHow Is Beyond Meat Expanding Its Retail Distribution Strategy?June 30, 2026 | zacks.comBeyond Meat Inc. stock rises Monday, outperforms marketJune 29, 2026 | marketwatch.comWhy Beyond Meat (BYND) Stock Is Up TodayJune 29, 2026 | finance.yahoo.comBeyond Meat® Launches Beyond Steak® Filet at Wegmans and H-E-BJune 29, 2026 | finance.yahoo.comBeyond Meat® Launches Beyond Steak® Filet at Wegmans and H-E-BJune 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026BYND, ALLO, and BTAI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.00 -0.10 (-4.76%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$2.00 +0.00 (+0.25%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.BioXcel Therapeutics NASDAQ:BTAI$0.82 -0.02 (-2.42%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.43%) As of 07/10/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Beyond Meat NASDAQ:BYND$0.66 -0.02 (-2.77%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.37%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beyond Meat, Inc., a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club stores, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was incorporated in 2008 and is headquartered in El Segundo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
